Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.
|Videos|July 8, 2022
Dr. Schaeffer discusses NCCN guideline development process
Author(s)Urology Times staff
“I think most panelists are happy to participate in those meetings, because generally speaking, those ad hoc meetings are done because there's a new advance in the field,” says Edward M. Schaeffer, MD, PhD.
Advertisement
In this video, Edward M. Schaeffer, MD, PHD, discusses the National Comprehensive Cancer Network’s process for updating its guidelines for prostate cancer. Schaeffer is chair and Harold Binstein Professor of Urology at Northwestern University Feinberg School of Medicine in Chicago, Illinois.
Advertisement
Related to this article
An analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
VIR-5500 is a PSMA-targeted PRO-XTEN dual-masked T-cell engager entering phase 3 development for prostate cancer.
Sri Sivalingam, MD, discusses how suction-based technologies are improving stone clearance and raising expectations for ureteroscopic stone treatment.
Based on these results, the trial protocol has been amended to move enrollment earlier in the course of disease progression.
Mark D. Tyson, II, MD, MPH, reviews emerging bladder-sparing therapies for NMIBC, highlighting cretostimogene data, treatment sequencing, and the need for comparative trials.
Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
Advertisement
Advertisement